Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | TK1 | P04183 | 2/20 | 0.60 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibacitabine SCHEMBL5981937 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL21423094 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL5981939 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL13812993 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL887475 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL225402 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL244921 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| SCHEMBL1635378 | 0.91 | DNMT1 (0.52) | DNMT1ADRB1TK1DNMT3BFPR2 | |
| SCHEMBL1635376 | 0.91 | DNMT1 (0.52) | DNMT1ADRB1TK1DNMT3BFPR2 | |
| Ibacitabine SCHEMBL9710365 | 0.91 | DNMT1 (0.54) | DNMT1ADRB1TK1DNMT3BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | claimed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2020081744-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | TOLLNINE, INC. (US) | 2020-04-23 | — | — | WO | claimed |
| EP-3610022-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | Tollnine, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| CN-110770345-A | Immunomodulatory polynucleotides, antibody conjugates, and methods of use thereof | 托尔奈公司 | 2020-02-07 | — | — | CN | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| WO-2018189382-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | SOLSTICE BIOLOGICS, LTD. (IE) | 2018-10-18 | — | — | WO | claimed |
| EP-3186387-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | Univerzita Palackého v Olomouci (CZ) | 2017-07-05 | — | — | EP | claimed |
| WO-2016029889-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-03-03 | — | — | WO | claimed |
| US-20090325897-A1 | DESIGNER THERAPY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2009-12-31 | — | — | US | claimed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | claimed |
| WO-2008085611-A2 | DESIGNER THERAPHY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2008-07-17 | — | — | WO | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| EP-0806956-B1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT | RESPROTECT GMBH (DE) | 2002-08-28 | — | — | EP | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104647-A1 | VACCINE | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106815-A1 | Z-INDUCING CHIMERA COMPOSITION | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TALLAC THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | TETRAGON BIOSCIENCE LTD. (IL) | 2026-04-21 | — | — | US | disclosed |
| US-12606863-B2 | Bioluminescent detection of DNA synthesis | PROMEGA CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12503730-B2 | Detectable nucleotide analogues | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20250283094-A1 | Modified Nucleosides | SOMALOGIC OPERATING CO., INC. (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4611757-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | Ramirez, Christina, M. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4591940-A2 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2025-07-30 | — | — | EP | disclosed |
| US-20250236911-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4233879-B1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2025-07-23 | — | — | EP | disclosed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| EP-3443001-B1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250041400-A1 | RSV VACCINE | ASTRAZENECA PHARMACEUTICALS LP | 2025-02-06 | — | — | US | disclosed |
| WO-2025017142-A1 | RSV VACCINE | ASTRAZENECA AB (SE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024238558-A1 | USE OF IMMUNOMODULATING TARGETED POLYNUCLEOTIDE CONJUGATES FOR USE WITH IMMUNE HONING AGENT | Tallac Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240382610-A1 | NECTIN-4 ANTIBODIES AND CONJUGATES | HORIZON TECHNOLOGY FINANCE CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20240376536-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240374746-A1 | SIRP-ALPHA ANTIBODIES AND CONJUGATES | HORIZON TECHNOLOGY FINANCE CORPORATION | 2024-11-14 | — | — | US | disclosed |
| US-20240342182-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | ELIAN LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240342200-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | ELIAN LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240343753-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240287528-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SOMALOGIC OPERATING CO., INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2024-07-04 | — | — | US | disclosed |
| EP-4392076-A1 | SIRP-ALPHA ANTIBODIES AND CONJUGATES | Tallac Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4388103-A1 | NECTIN-4 ANTIBODIES AND CONJUGATES | Tallac Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118239996-A | Application of fluorescent labeled nucleotide in DNA synthesis sequencing and single molecule sequencing | 上海交通大学 | 2024-06-25 | — | — | CN | disclosed |
| US-20240191242-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2024-06-13 | — | — | US | disclosed |
| US-12006540-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-11 | — | — | US | disclosed |
| US-11999999-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2024097158-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | RAMIREZ CHRISTINA M (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | HEMISPHERIAN AS (NO) | 2024-04-23 | — | — | US | disclosed |
| US-11959137-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| EP-4342545-A2 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | Elian LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4337646-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | Promega Corporation (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| WO-2024050372-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-11920136-B2 | Transglutaminase-mediated conjugation | Tallac Therapeutics, Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4323374-A1 | MODIFIED NUCLEOSIDES | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117567536-A | Application of fluorescent labeled nucleotide in DNA synthesis sequencing and single molecule sequencing | 上海交通大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-4312942-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117343990-A | Method and kit for determining target polynucleotide and probe set | 牛津纳米孔科技公开有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| CN-117242085-A | Modified nucleosides | 私募蛋白质体操作有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230364255-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2023-11-16 | — | — | US | disclosed |
| EP-3166680-B1 | ANTI-HSV PRE-EXPOSURE PROPHYLAXIS | ELIAN LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11795463-B2 | Transglutaminase-mediated conjugation | Tallac Therapeutics, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230310439-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | ELIAN LLC | 2023-10-05 | — | — | US | disclosed |
| US-20230295694-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-4233879-A1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2023-08-30 | — | — | EP | disclosed |
| CN-116670161-A | Methods of preventing or treating viral-induced organ injury or failure using IL-22 dimers | 亿一生物医药开发(上海)有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-11725205-B2 | Methods and polynucleotides for amplifying a target polynucleotide | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2023147565-A2 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | Opentrons LabWorks Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230233608-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3917538-B1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2023-07-12 | — | — | EP | disclosed |
| US-11696918-B2 | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | ELIAN LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-11649451-B2 | Evolution of bioactive sequence-defined synthetic polymers using DNA-templated polymerization | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649451-B2 | Evolution of bioactive sequence-defined synthetic polymers using DNA-templated polymerization | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230130194-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-11633385-B2 | Combination compositions for treatment of cancer | REDHILL BIOPHARMA LTD. (IL) | 2023-04-25 | — | — | US | disclosed |
| US-20230079150-A1 | METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER | Evive Biotechnology (Shanghai) Ltd (CN) | 2023-03-16 | — | — | US | disclosed |
| WO-2023028511-A1 | SIRP-ALPHA ANTIBODIES AND CONJUGATES | Tallac Therapeutics, Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023023659-A1 | NECTIN-4 ANTIBODIES AND CONJUGATES | Tallac Therapeutics, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230046363-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4123031-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | The Regents of The University of California (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4110830-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | Tallac Therapeutics, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11542551-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-01-03 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| EP-4103219-A1 | METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER | Evive Biotechnology (Shanghai) Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-20220396830-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | PROMEGA CORPORATION | 2022-12-15 | — | — | US | disclosed |
| EP-3529373-B1 | METHOD FOR DETERMINING THE PRESENCE, ABSENCE OR AMOUNT OF TWO OR MORE TARGET POLYNUCLEOTIDES | OXFORD NANOPORE TECH PLC (GB) | 2022-12-07 | — | — | EP | disclosed |
| US-20220380768-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-12-01 | — | — | US | disclosed |
| WO-2022241249-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | PROMEGA CORPORATION (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220347112-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2022221241-A1 | MODIFIED NUCLEOSIDES | SOMALOGIC OPERATING CO., INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022212576-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-114989235-A | Design and synthesis of nucleotides based on novel disulfide linkers for use as reversible terminators for DNA sequencing by synthesis | 哥伦比亚大学董事会 | 2022-09-02 | — | — | CN | disclosed |
| US-20220257629-A1 | COMPOSITIONS AND METHODS FOR UPREGULATION OF HUMAN FETAL HEMOGLOBIN | THE UAB RESEARCH FOUNDATION | 2022-08-18 | — | — | US | disclosed |
| US-11390904-B2 | Nanopore-based method and double stranded nucleic acid construct therefor | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-07-19 | — | — | US | disclosed |
| US-11390910-B2 | Method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-07-19 | — | — | US | disclosed |
| US-20220213541-A1 | METHOD FOR DETERMINING A POLYMER SEQUENCE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-3283499-B1 | DUAL QUENCHER PROBES | BIOSEARCH TECH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-108779138-B | Design and synthesis of nucleotides based on novel disulfide linkers for use as reversible terminators for DNA sequencing by synthesis | 哥伦比亚大学董事会 | 2022-06-17 | — | — | CN | disclosed |
| EP-3283638-B1 | METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME | UNIV CALIFORNIA (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114469958-A | Method for prophylactic treatment of viruses and pre-exposure prophylactic kit | 艾利安有限责任公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | LG ELECTRONICS INC. (KR) | 2022-04-28 | — | — | US | disclosed |
| US-20220117992-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2022-04-21 | — | — | US | disclosed |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| WO-2022040173-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | Tallac Therapeutics, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| CN-111732623-B | Tri-isopropyl silaacetylene modified deoxycytidine phosphoramidite monomer and preparation method and application thereof | 中国科学院化学研究所 | 2022-01-18 | — | — | CN | disclosed |
| CN-106794336-B | Method for prophylactic treatment of viruses and pre-exposure prophylactic kit | 艾利安有限责任公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3930721-A1 | TREATMENT OF HERPES SIMPLEX WITH A COMBINATION OF VALACYCLOVIR AND FAMCICLOVIR | Elian LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210403978-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-30 | — | — | US | disclosed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3917538-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2021-12-08 | — | — | EP | disclosed |
| CN-113727715-A | Treatment of herpes simplex with a combination of valacyclovir and famciclovir | 艾利安有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| US-11180522-B2 | Disulfide-linked reversible terminators | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (KY) | 2021-11-23 | — | — | US | disclosed |
| US-11180523-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-20210346410-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | ELIAN LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| CN-107922454-B | Dual quencher probes | 生物检索技术股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-11149296-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-19 | — | — | US | disclosed |
| WO-2021160163-A1 | METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER | Evive Biotechnology (Shanghai) Ltd (CN) | 2021-08-19 | — | — | WO | disclosed |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-10 | — | — | US | disclosed |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-10 | — | — | US | disclosed |
| US-11071745-B2 | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | ELIAN LLC (US) | 2021-07-27 | — | — | US | disclosed |
| CN-107109483-B | Method for modifying template double-stranded polynucleotide | 牛津纳米孔技术公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-3847278-A1 | METHOD FOR DETERMINING A POLYMER SEQUENCE | Oxford Nanopore Technologies Limited (GB) | 2021-07-14 | — | — | EP | disclosed |
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | SONIC MASTER LTD (VG) | 2021-07-01 | — | — | US | disclosed |
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | SONIC MASTER LTD (VG) | 2021-07-01 | — | — | US | disclosed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | REDHILL BIOPHARMA LTD (IL) | 2021-05-06 | — | — | US | disclosed |
| EP-3794142-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | Oxford Nanopore Technologies Limited (GB) | 2021-03-24 | — | — | EP | disclosed |
| EP-3795577-A1 | MODIFIED NUCLEOTIDES | Illumina Cambridge Limited (GB) | 2021-03-24 | — | — | EP | disclosed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-10933068-B2 | Modulators of DUX4 for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2021-03-02 | — | — | US | disclosed |
| US-20210047646-A1 | Compositions Comprising Immune System Activators and Method of Using Same | THE TRUSTEES OF PRINCETON UNIVERSITY | 2021-02-18 | — | — | US | disclosed |
| WO-2021021999-A1 | COMPOSITIONS AND METHODS FOR UPREGULATION OF HUMAN FETAL HEMOGLOBIN | THE UAB RESEARCH FOUNDATION (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20200399692-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2020-12-24 | — | — | US | disclosed |
| US-20200397791-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | ELIAN LLC | 2020-12-24 | — | — | US | disclosed |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200318179-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-10-08 | — | — | US | disclosed |
| CN-111732623-A | Tri-isopropyl silaacetylene modified deoxycytidine phosphoramidite monomer and preparation method and application thereof | 中国科学院化学研究所 | 2020-10-02 | — | — | CN | disclosed |
| US-20200291452-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
| WO-2020157335-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2020-08-06 | — | — | WO | disclosed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| US-20200232005-A1 | Methods of Producing and Using Single-Stranded Deoxyribonucleic Acids and Compositions for Use in Practicing the Same | TAKARA BIO USA, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20200208211-A1 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200172896-A1 | EVOLUTION OF BIOACTIVE SEQUENCE-DEFINED SYNTHETIC POLYMERS USING DNA-TEMPLATED POLYMERIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-04 | — | — | US | disclosed |
| US-10669538-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2020-06-02 | — | — | US | disclosed |
| US-10669538-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2020-06-02 | — | — | US | disclosed |
| US-10669578-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-06-02 | — | — | US | disclosed |
| US-20200147110-A9 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | Prophylaxis LLC | 2020-05-14 | — | — | US | disclosed |
| WO-2020081744-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | TOLLNINE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-3587433-B1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LTD (GB) | 2020-04-22 | — | — | EP | disclosed |
| CN-111018930-A | TPE-2' -deoxynucleoside, fluorescent gel, and preparation methods and applications thereof | 深圳大学 | 2020-04-17 | — | — | CN | disclosed |
| US-20200113881-A1 | METHOD FOR TREATING CANCER WITH COMBINATION THERAPY | REDHILL BIOPHARMA LTD (IL) | 2020-04-16 | — | — | US | disclosed |
| EP-3363809-B1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | ILLUMINA CAMBRIDGE LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2020069424-A1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | CENTRILLION TECHNOLOGIES, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-10584363-B2 | Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same | TAKARA BIO USA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-10570440-B2 | Method for modifying a template double stranded polynucleotide using a MuA transposase | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-02-25 | — | — | US | disclosed |
| EP-3610022-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | Tollnine, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-106536483-B | Coomic quenching agent | 生物检索技术股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200032248-A1 | METHOD | Oxford Nanopore Technologies Inc. (GB) | 2020-01-30 | — | — | US | disclosed |
| US-20200030345-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | ELIAN LLC (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2019227526-A1 | FLUORESCENTLY LABELLED NUCLEOTIDE AND PREPARATION METHOD AND USE THEREOF | 苏州百源基因技术有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| CN-105658658-B | Cytidine-5-formyl amine-modified polynucleotide composition and its correlation technique | 私募蛋白质体公司 | 2019-11-05 | — | — | CN | disclosed |
| US-10463654-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2019-11-05 | — | — | US | disclosed |
| EP-3126517-B1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2019199720-A1 | COMPOSITIONS COMPRISING IMMUNE SYSTEM ACTIVATORS AND METHOD OF USING SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190298727-A1 | MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LIMITED (VG) | 2019-10-03 | — | — | US | disclosed |
| US-20190249231-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20190248827-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| CN-110121562-A | Method of producing a composite material | 牛津纳米孔技术公司 | 2019-08-13 | — | — | CN | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10301310-B2 | Cosmic quenchers | BIOSEARCH TECHNOLOGIES, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190136308-A1 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-05-09 | — | — | US | disclosed |
| US-10273261-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190077726-A1 | METHODS OF SYNTHESIZING LABELED NUCLEOSIDES | SINGULAR GENOMICS SYSTEMS INC (US) | 2019-03-14 | — | — | US | disclosed |
| EP-3443001-A2 | REGULATED BIOCIRCUIT SYSTEMS | Obsidian Therapeutics, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3091026-B1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | CENTRILLION TECH HOLDINGS CORP (KY) | 2019-02-20 | — | — | EP | disclosed |
| WO-2019010441-A1 | EVOLUTION BIOACTIVE SEQUENCE-DEFINED SYNTHETIC POLYMERS USING DNA-TEMPLATED POLYMERIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-10 | — | — | WO | disclosed |
| US-20190004055-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2019-01-03 | — | — | US | disclosed |
| EP-3140286-B1 | COSMIC QUENCHERS | BIOSEARCH TECH INC (US) | 2018-12-26 | — | — | EP | disclosed |
| EP-3207152-B1 | METHOD | OXFORD NANOPORE TECH LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| EP-3108010-B1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECH LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-20180312536-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2018-11-01 | — | — | US | disclosed |
| WO-2018189382-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | SOLSTICE BIOLOGICS, LTD. (IE) | 2018-10-18 | — | — | WO | disclosed |
| US-20180274024-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-09-27 | — | — | US | disclosed |
| EP-3363809-A1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Illumina Cambridge Limited (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-10052329-B2 | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | ELIAN LLC (US) | 2018-08-21 | — | — | US | disclosed |
| WO-2018143893-A1 | IDOXURIDINE AND ITS ANALOGS AS NEUROPROTECTANS FOR THE TREATMENT OF PARKINSONISM | SVENNINGSSON PER (SE) | 2018-08-09 | — | — | WO | disclosed |
| EP-3356381-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | The Trustees of Columbia University in the City of New York (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | disclosed |
| CN-108136207-A | Combination therapy for the treatment of cancer | 红山生物医药有限公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-3330277-A2 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3330277-A2 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD (IL) | 2018-05-10 | — | — | US | disclosed |
| US-20180100181-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-12 | — | — | US | disclosed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-3002289-B1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | ILLUMINA CAMBRIDGE LTD (GB) | 2018-02-28 | — | — | EP | disclosed |
| EP-3283499-A1 | DUAL QUENCHER PROBES | Biosearch Technologies, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283638-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | The Regents of The University of California (US) | 2018-02-21 | — | — | EP | disclosed |
| CN-107614699-A | Method for detecting agglutination and composition for practicing the method | 加利福尼亚大学董事会 | 2018-01-19 | — | — | CN | disclosed |
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-20170349927-A1 | METHODS OF PRODUCING AND USING SINGLE-STRANDED DEOXYRIBONUCLEIC ACIDS AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | TAKARA BIO USA, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9803240-B2 | Stabilized nucleic acid dark quencher-fluorophore probes | BIOSEARCH TECHNOLOGIES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| WO-2017180587-A2 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170240955-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2017-08-24 | — | — | US | disclosed |
| EP-3207152-A1 | METHOD | Oxford Nanopore Technologies Limited (GB) | 2017-08-23 | — | — | EP | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| EP-3186387-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | Univerzita Palackého v Olomouci (CZ) | 2017-07-05 | — | — | EP | disclosed |
| EP-3186387-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | Univerzita Palackého v Olomouci (CZ) | 2017-07-05 | — | — | EP | disclosed |
| EP-2757091-B1 | Stabilized Nucleic Acid Dark Quencher-Fluorophore Probes | BIOSEARCH TECH INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9688980-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION (DK) | 2017-06-27 | — | — | US | disclosed |
| US-9688980-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION (DK) | 2017-06-27 | — | — | US | disclosed |
| US-9688980-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION (DK) | 2017-06-27 | — | — | US | disclosed |
| EP-3166680-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | Prophylaxis, LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20170114058-A1 | COSMIC QUENCHERS | BIOSEARCH TECHNOLOGIES, INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2017060771-A2 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-13 | — | — | WO | disclosed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| WO-2017048982-A1 | OLIGOPHOSPHATE DARK QUENCHERS AND USES | BIOSEARCH TECHNOLOGIES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-9598456-B2 | Modified cytosine polynucleotide oligomers and methods | CEPHEID (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3140286-A1 | COSMIC QUENCHERS | Biosearch Technologies, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170067101-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2017-03-09 | — | — | US | disclosed |
| EP-3126517-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | Cepheid (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-3108010-A1 | SAMPLE PREPARATION METHOD | Oxford Nanopore Technologies Limited (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-9528151-B2 | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| CN-106232834-A | Sample preparation methods | 牛津纳米孔技术公司 | 2016-12-14 | — | — | CN | disclosed |
| US-20160326576-A1 | DUAL QUENCHER PROBES | BIOSEARCH TECHNOLOGIES, INC. | 2016-11-10 | — | — | US | disclosed |
| WO-2016168750-A1 | DUAL QUENCHER PROBES | BIOSEARCH TECHNOLOGIES, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168711-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-3071588-A1 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9410189-B2 | Methods of preventing non-specific reactions of nucleotide sequences | CO-DIAGNOSTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2016-07-28 | — | — | US | disclosed |
| US-9388464-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-07-12 | — | — | US | disclosed |
| CN-105658658-A | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | 私募蛋白质体公司 | 2016-06-08 | — | — | CN | disclosed |
| US-20160139133-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2016-05-19 | — | — | US | disclosed |
| WO-2016059363-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2016-04-21 | — | — | WO | disclosed |
| EP-3002289-A1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Illumina Cambridge Limited (GB) | 2016-04-06 | — | — | EP | disclosed |
| WO-2016029889-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016029889-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-03-03 | — | — | WO | disclosed |
| EP-2305808-B1 | Templated molecules and methods for using such molecules | NUEVOLUTION AS (DK) | 2016-03-02 | — | — | EP | disclosed |
| EP-2305808-B1 | Templated molecules and methods for using such molecules | NUEVOLUTION AS (DK) | 2016-03-02 | — | — | EP | disclosed |
| EP-1905829-B1 | Templated molecules and methods for using such molecules | NUEVOLUTION AS (DK) | 2016-02-17 | — | — | EP | disclosed |
| US-20160032378-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| WO-2016007538-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | PROPHYLAXIS, LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160000797-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | ELIAN LLC | 2016-01-07 | — | — | US | disclosed |
| WO-2015172134-A1 | COSMIC QUENCHERS | BIOSEARCH TECHNOLOGIES, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315567-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2015-11-05 | — | — | US | disclosed |
| US-20150315567-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2015-11-05 | — | — | US | disclosed |
| US-20150315567-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2015-11-05 | — | — | US | disclosed |
| WO-2015153510-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150275283-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2607369-B1 | Modified nucleotides for polynucleotide sequencing | ILLUMINA CAMBRIDGE LTD (GB) | 2015-09-23 | — | — | EP | disclosed |
| US-9121060-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| WO-2015124935-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015077292-A1 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | SOMALOGIC, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-8932992-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-8921124-B2 | Pyrazole-based cyanine dye | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140315191-A1 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2770058-A1 | Ligand and method for detection of okadaic acid | Université de Perpignan (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20140221639-A1 | RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2014-08-07 | — | — | US | disclosed |
| US-20140221639-A1 | RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2014-08-07 | — | — | US | disclosed |
| EP-2757091-A1 | Stabilized Nucleic Acid Dark Quencher-Fluorophore Probes | Biosearch Technologies, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140194611-A1 | STABILIZED NUCLEIC ACID DARK QUENCHER-FLUOROPHORE PROBES | BIOSEARCH TECHNOLOGIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8674094-B2 | Stabilized nucleic acid dark quencher-fluorophore probes | BIOSEARCH TECHNOLOGIES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8614312-B2 | Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-24 | — | — | US | disclosed |
| US-8597881-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2013-12-03 | — | — | US | disclosed |
| US-20130280700-A1 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-24 | — | — | US | disclosed |
| US-8512559-B2 | Device, method, and system for separation and detection of biomolecules and cells | INTEL CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2607369-A1 | Modified nucleotides for polynucleotide sequencing | Illumina Cambridge Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-8466266-B2 | Stabilized nucleic acid dark quencher-fluorophore probes | BIOSEARCH TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8410075-B2 | Mannich base N-oxide drugs | CASCADE PRODRUG INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1530578-B1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | ILLUMINA CAMBRIDGE LTD (GB) | 2013-03-13 | — | — | EP | disclosed |
| US-8298792-B2 | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-10-30 | — | — | US | disclosed |
| US-8298792-B2 | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120225494-A1 | DNA LIGANDS FOR AFLATOXIN AND ZEARALENONE | LE LINDA CHRYSEIS (CA) | 2012-09-06 | — | — | US | disclosed |
| WO-2012113072-A1 | A METHOD FOR THE SELECTION OF DNA LIGANDS FOR A MOLECULAR TARGET | NEOVENTURES BIOTECHNOLOGY INC. (CA) | 2012-08-30 | — | — | WO | disclosed |
| US-8252768-B2 | Designer therapy of pancreatic tumors | UNIVERSITY OF MIAMI (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120178919-A1 | RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF | NATIONAL YANG-MING UNIVERSITY (TW) | 2012-07-12 | — | — | US | disclosed |
| US-20120178919-A1 | RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF | NATIONAL YANG-MING UNIVERSITY (TW) | 2012-07-12 | — | — | US | disclosed |
| US-20120178919-A1 | RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF | NATIONAL YANG-MING UNIVERSITY (TW) | 2012-07-12 | — | — | US | disclosed |
| EP-2467483-A1 | DNA LIGANDS FOR AFLATOXIN AND ZEARALENONE | Neoventures Biotechnology Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| US-8193335-B2 | Click chemistry for the production of reporter molecules | BASECLICK GMBH (DE) | 2012-06-05 | — | — | US | disclosed |
| WO-2012033298-A3 | METHOD FOR MANUFACTURING A NOX GAS SENSOR, AND NOX GAS SENSOR MANUFACTURED USING SAME | 일진머티리얼즈 주식회사 (KR) | 2012-05-10 | — | — | WO | disclosed |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120045796-A1 | NUCLEIC ACID HOTSTART TECHNOLOGY | CO-DIAGNOSTICS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-8105770-B2 | Method of detecting amplification or deletion in genomic DNA Fragment | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20120021408-A1 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2012-01-26 | — | — | US | disclosed |
| US-20120021408-A1 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2012-01-26 | — | — | US | disclosed |
| US-20120004391-A2 | CYANINE-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | Cyanine Technologies S.p.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-8071739-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| EP-2006289-B1 | PYRAZOLE-TYPE CYANINE DYE | WAKO PURE CHEM IND LTD (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-8062841-B2 | Multiplex data collection and analysis in bioanalyte detection | INTEL CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110282041-A1 | STABILIZED NUCLEIC ACID DARK QUENCHER-FLUOROPHORE PROBES | BIOSEARCH TECHNOLOGIES, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2089343-B1 | CLICK CHEMISTRY FOR THE PRODUCTION OF REPORTER MOLECULES | BASECLICK GMBH (DE) | 2011-07-06 | — | — | EP | disclosed |
| US-20110118438-A1 | CYANINE-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | Cyanine Technologies S.p.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-2305808-A1 | Templated molecules and methods for using such molecules | Nuevolution A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305808-A1 | Templated molecules and methods for using such molecules | Nuevolution A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011020198-A1 | DNA LIGANDS FOR AFLATOXIN AND ZEARALENONE | NEOVENTURES BIOTECHNOLOGY LIMITED (CA) | 2011-02-24 | — | — | WO | disclosed |
| US-7892297-B2 | Cyanin-type compounds having an alkynyl linker arm | Cyanine Technologies S.p.A. (IT) | 2011-02-22 | — | — | US | disclosed |
| EP-2268608-A2 | STABILIZED NUCLEIC ACID DARK QUENCHER-FLUOROPHORE PROBES | Biosearch Technologies, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100317004-A1 | PROBES | Life Technologies Corporation (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100290992-A1 | NANOPARTICLE NUCLEIC ACID BINDING COMPOUND CONJUGATES FORMING I-MOTIFS | ROCHE DIAGNOSTICS GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292452-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LTD | 2010-11-18 | — | — | US | disclosed |
| US-20100290992-A1 | NANOPARTICLE NUCLEIC ACID BINDING COMPOUND CONJUGATES FORMING I-MOTIFS | ROCHE DIAGNOSTICS GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-2242761-A1 | METHOD OF MYCOTOXIN DETECTION | Neoventures Biotechnology Inc. (CA) | 2010-10-27 | — | — | EP | disclosed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-7771973-B2 | sequencing reactions where nucleotide or nucleoside molecules modified by reversible covalent attachment of 3'-OH blocking groups thereto, are used where blocked nucleotide or nucleoside molecules are required | ILLUMINA CAMBRIDGE LIMITED (GB) | 2010-08-10 | — | — | US | disclosed |
| US-7727713-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2010-06-01 | — | — | US | disclosed |
| US-20100112711-A1 | METHOD OF DETECTING AMPLIFICATION OR DELETION IN GENOMIC DNA FRAGMENT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100081137-A1 | Click Chemistry for the Production of Reporter Molecules | BASECLICK GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016177-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20090325897-A1 | DESIGNER THERAPY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325172-A1 | Modified nucleotides | SOLEXA LIMITED | 2009-12-31 | — | — | US | disclosed |
| EP-2136626-A1 | MANNICH BASE N-OXIDE DRUGS | State of Oregon acting by and through the Oregon State Board of Higher Education on behalf of the University of Oregon (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-2119797-A1 | METHOD OF DETECTING AMPLIFICATION OR DELETION IN GENOMIC DNA FRAGMENT | Wako Pure Chemical Industries, Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119797-A1 | METHOD OF DETECTING AMPLIFICATION OR DELETION IN GENOMIC DNA FRAGMENT | Wako Pure Chemical Industries, Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090259030-A1 | STABILIZED NUCLEIC ACID DARK QUENCHER-FLUOROPHORE PROBES | BIOSEARCH TECHNOLOGIES (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009124150-A2 | STABILIZED NUCLEIC ACID DARK QUENCHER-FLUOROPHORE PROBES | BIOSEARCH TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| EP-2089343-A2 | CLICK CHEMISTRY FOR THE PRODUCTION OF REPORTER MOLECULES | baseclick GmbH (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009086621-A1 | METHOD OF MYCOTOXIN DETECTION | NEOVENTURES BIOTECHNOLOGY INC. (CA) | 2009-07-16 | — | — | WO | disclosed |
| US-7541444-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2009-06-02 | — | — | US | disclosed |
| EP-2054085-A2 | NANOPARTICLE NUCLEIC ACID BONDING COMPOUND CONJUGATES FORMING I-MOTIFS | Roche Diagnostics GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20090069546-A1 | PYRAZOLE-BASED CYANINE DYE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-7488607-B2 | Electronically readable microarray with electronic addressing function | AGILENT TECHNOLOGIES, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20090005260-A1 | MULTIPLEX DATA COLLECTION AND ANALYSIS IN BIOANALYTE DETECTION | INTEL CORPORATION | 2009-01-01 | — | — | US | disclosed |
| EP-2006289-A1 | PYRAZOLE-TYPE CYANINE DYE | Wako Pure Chemical Industries, Ltd. (JP) | 2008-12-24 | — | — | EP | disclosed |
| EP-1985702-A2 | CPG-like nucleic acids and methods of use thereof | Coley Pharmaceuticals GmbH (DE) | 2008-10-29 | — | — | EP | disclosed |
| US-20080262989-A1 | MULTIPLEX DATA COLLECTION AND ANALYSIS IN BIOANALYTE DETECTION | INTEL CORPORATION | 2008-10-23 | — | — | US | disclosed |
| WO-2008115499-A1 | MANNICH BASE N-OXIDE DRUGS | STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080226649-A1 | CPG-like nucleic acids and methods of use thereof | COLEY PHARMACEUTICAL GMBH (DE) | 2008-09-18 | — | — | US | disclosed |
| US-7410763-B2 | Multiplex data collection and analysis in bioanalyte detection | INTEL CORPORATION (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1952155-A2 | METHOD AND CMOS-BASED DEVICE TO ANALYZE MOLECULES AND NANOMATERIALS BASED ON THE ELECTRICAL READOUT OF SPECIFIC BINDING EVENTS ON FUNCTIONALIZED ELECTRODES | Intel Corporation (INTEL) (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008085611-A2 | DESIGNER THERAPHY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2008-07-17 | — | — | WO | disclosed |
| US-7399844-B2 | Method and reagents for analyzing the nucleotide sequence of nucleic acids | AGILENT TECHNOLOGIES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1350262-B1 | CPG-LIKE NUCLEIC ACIDS AND METHODS OF USE THEREOF | COLEY PHARMACEUTICALS GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1383890-B1 | MUTANTS OF DESOXYCYTIDINE KINASE HAVING EXTENDED ENZYMATIC ACTIVITY | PASTEUR INSTITUT (FR) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008052775-A2 | CLICK CHEMISTRY FOR THE PRODUCTION OF REPORTER MOLECULES | BASECLICK GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008052775-A2 | CLICK CHEMISTRY FOR THE PRODUCTION OF REPORTER MOLECULES | BASECLICK GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008048222-A2 | METHOD AND CMOS-BASED DEVICE TO ANALYZE MOLECULES AND NANOMATERIALS BASED ON THE ELECTRICAL READOUT OF SPECIFIC BINDING EVENTS ON FUNCTIONALIZED ELECTRODES | INTEL CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1905829-A2 | Templated molecules and methods for using such molecules | Nuevolution A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008017507-A2 | NANOPARTICLE NUCLEIC ACID BONDING COMPOUND CONJUGATES FORMING I-MOTIFS | ROCHE DIAGNOSTICS GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| US-7323555-B2 | Nucleotide derivative and DNA microarray | ISAO SAITO (JP) | 2008-01-29 | — | — | US | disclosed |
| US-20070292855-A1 | Method and CMOS-based device to analyze molecules and nanomaterials based on the electrical readout of specific binding events on functionalized electrodes | INTEL CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1402024-B1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION AS (DK) | 2007-08-22 | — | — | EP | disclosed |
| US-20070166705-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| EP-1251136-B1 | Method and reagents for analyzing the nucleotide sequence of nucleic acids | AGILENT TECHNOLOGIES INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070114180-A1 | Device, method, and system for separation and detection of biomolecules and cells | INTEL CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| EP-1585835-B1 | Nucleic acid probes and method for detecting a target nucleic acid sequence comprising two or more cis-located nucleic acid regions | DYNAL BIOTECH LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20070048746-A1 | Beam emitter, microfluidic channel, spectrometer and detector; binding between reporter molecules and analyte; microelectric mechanical system | INTEL CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060269916-A1 | Probes | DYNAL BIOTECH INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060230554-A1 | Cyanin-type compounds having an alkynyl linker arm | CYANINE TECHNOLOGIES S. P. A. (IT) | 2006-10-19 | — | — | US | disclosed |
| US-20060216312-A1 | Mutants of replication competent vaccinia virus | ARIZONA BOARD OF REGENTS, ACTING FOR AND ON BEHALF OF, ARIZONA STATE UNIVERSITY | 2006-09-28 | — | — | US | disclosed |
| EP-1689439-A2 | SMALL MOLECULE COMPOSITIONS AND METHODS FOR INCREASING DRUG EFFICIENCY USING COMPOSITIONS THEREOF | Acidophil LLC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7057027-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1654327-A1 | CYANIN-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | Caputo, Giuseppe (IT) | 2006-05-10 | — | — | EP | disclosed |
| US-6967079-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6962783-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1585835-A2 | NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS | Dynal Biotech Limited (GB) | 2005-10-19 | — | — | EP | disclosed |
| EP-1015643-B1 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | AGILENT TECHNOLOGIES INC (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050148534-A1 | Small molecule compositions and methods for increasing drug efficiency using compositions thereof | ACIDOPHIL LLC | 2005-07-07 | — | — | US | disclosed |
| US-6914148-B2 | Guanidinium functionalized intermediates | ISIS PHARMACEUTICALS, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1530578-A2 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Solexa Limited (GB) | 2005-05-18 | — | — | EP | disclosed |
| US-20050079505-A1 | Electronically readable microarray with electronic addressing function | AGILENT TECHNOLOGIES INC | 2005-04-14 | — | — | US | disclosed |
| WO-2005030258-A2 | SMALL MOLECULE COMPOSITIONS AND METHODS FOR INCREASING DRUG EFFICIENCY USING COMPOSITIONS THEREOF | ACIDOPHIL LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6875593-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20050069905-A1 | Detection of molecular binding events | AGILENT TECHNOLOGIES, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005014723-A1 | CYANIN-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | CAPUTO GIUSEPPE (IT) | 2005-02-17 | — | — | WO | disclosed |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | FROEHLER BRIAN (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040248104-A1 | Methods and reagents for profiling quantities of nucleic acids | AGILENT TECHNOLOGIES, INC. | 2004-12-09 | — | — | US | disclosed |
| US-6825331-B2 | DIAGNOSTIC HYBRIDIZATION PROBES; BIOCHEMICAL CONJUGATION | ISIS PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040220395-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004087047-A2 | MUTANTS OF REPLICATION COMPETENT VACCINIA VIRUS | ARIZONA BOARD OF REGENTS (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004048611-A2 | NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS | DYNAL BIOTECH LIMITED (GB) | 2004-06-10 | — | — | WO | disclosed |
| EP-1404370-A2 | OPHTHALMIC COMPOSITIONS COMPRISING HYALURONIC ACID | Novartis AG (CH) | 2004-04-07 | — | — | EP | disclosed |
| EP-1402024-A2 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | Nuevolution A/S (DK) | 2004-03-31 | — | — | EP | disclosed |
| EP-1401850-A1 | NUCLEOSIDE DERIVATIVES FOR LIBRARY PREPARATION | Nuevolution A/S (DK) | 2004-03-31 | — | — | EP | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| US-20040049008-A1 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2004-03-11 | — | — | US | disclosed |
| WO-2004018497-A2 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | SOLEXA LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | MATTEUCCI MARK D (US) | 2003-11-06 | — | — | US | disclosed |
| EP-1350262-A2 | CPG-LIKE NUCLEIC ACIDS AND METHODS OF USE THEREOF | Coley Pharmaceuticals GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| US-6627456-B1 | Incorporating into the oligonucleotide analogs that are the components of a library to which in vitro selection methods functionalized standard and non-standard nucleotides, and incorporating functionalized cofactors into the experiment | BENNER, STEVEN | 2003-09-30 | — | — | US | disclosed |
| US-20030181406-A1 | CpG-like nucleic acids and methods of use thereof | PFIZER INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | FROEHLER BRIAN (US) | 2003-09-11 | — | — | US | disclosed |
| US-6617437-B1 | Modified oligonucleotide of given formula; useful in diagnostics and therapeutics | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20030143561-A1 | Nucleoside derivatives for library preparation | NUEVOLUTION A/S (DK) | 2003-07-31 | — | — | US | disclosed |
| US-6593466-B1 | Monomer of given formula; modified to increase binding affinity to target DNA or RNA and resist nuclease degradation; useful as therapeutics or diagnostics; gene expression inhibition | ISIS PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-6589941-B1 | Preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation | RESPROTECT GMBH (DE) | 2003-07-08 | — | — | US | disclosed |
| US-20030113769-A1 | Aminooxy functionalized oligomers, oligomer arrays and methods of using them | IONIS PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6576752-B1 | Oligonucleotide comprising a plurality of nucleotide units of given structure; useful for diagnostic, therapeutic and investigative purposes | ISIS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030092046-A1 | Guanidinium functionalized oligomers and methods | MANOHARAN MUTHIAH (US) | 2003-05-15 | — | — | US | disclosed |
| EP-0719272-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6534639-B1 | Useful for diagnostic, therapeutic and investigative purposes; guanidine group gives enhanced DNA-RNA hybrid binding affinity and/or increased nuclease resistance | ISIS PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20030022150-A1 | Detecting preferential bioplymers in sample; obtain nutrient broths inoculate with cells, immerse electrodes, code cells, incubate cells with substrate, monitor response, evaluate response | AGILENT TECHNOLOGIES, INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002102820-A1 | NUCLEOSIDE DERIVATIVES FOR LIBRARY PREPARATION | NUEVOLUTION A/S (DK) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002103008-A2 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002100436-A2 | OPHTHALMIC ONCE-A-DAY COMPOSITION | NOVARTIS AG (CH) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100437-A2 | OPHTHALMIC COMPOSITIONS COMPRISING HYALURONIC ACID | NOVARTIS AG (CH) | 2002-12-19 | — | — | WO | disclosed |
| US-20020182601-A1 | Method and reagents for analyzing the nucleotide sequence of nucleic acids | AGILENT TECHNOLOGIES, INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1256589-A2 | Oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1251136-A2 | Method and reagents for analyzing the nucleotide sequence of nucleic acids | Agilent Technologies, Inc. (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1206574-A4 | GUANIDINIUM FUNCTIONALIZED OLIGOMERS AND METHODS | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002069369-A2 | CPG-LIKE NUCLEIC ACIDS AND METHODS OF USE THEREOF | COLEY PHARMACEUTICAL GMBH (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-0806956-B1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT | RESPROTECT GMBH (DE) | 2002-08-28 | — | — | EP | disclosed |
| EP-1206574-A2 | GUANIDINIUM FUNCTIONALIZED OLIGOMERS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001002423-A9 | 2'-GUANIDINYL-SUBSTITUTED OLIGONUCLEOTIDES AND GENE EXPRESSION MODULATION THEREWITH | ISIS PHARMACEUTICALS INC (US) | 2002-05-02 | — | — | WO | disclosed |
| US-6380368-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6342217-B1 | ADMINISTERING 5-HALOGENATED PYRIMIDINE DERIVATIVE TO CONFER RADIATION SENSITIVITY TO TUMOR CELLS, EXPOSING TUMOR CELLS TO RADIATION THERAPY TO KILL TUMOR CELLS | HUMAN GENE THERAPY RESEARCH INSTITUTE | 2002-01-29 | — | — | US | disclosed |
| US-6218118-B1 | MIXTURE OF NATURAL AND MASS-MODIFIED GENERIC OLIGONUCLEOTIDE PRECURSORS; USING MIXTURE AND ENZYMATIC PROCESSES TO ALTER THE LENGTH, AND THUS THE MASS, OF PRECURSORS THAT ARE COMPLEMENTARY TO TARGET NUCLEIC ACID | AGILENT TECHNOLOGIES, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-0923591-A4 | NOVEL BORONIC ACID-CONTAINING NUCLEIC ACIDS AND THEIR USE AS DIAGNOSTIC AGENTS | PROLINX INC (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-2001002423-A2 | 2'-GUANIDINYL-SUBSTITUTED OLIGONUCLEOTIDES AND GENE EXPRESSION MODULATION THEREWITH | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| US-6162459-A | Acyclovir transdermal delivery system | NATIONAL SCIENCE COUNCIL (TW) | 2000-12-19 | — | — | US | disclosed |
| US-6136332-A | NONAQUEOUS, TOPICAL | SOCIETE L'OREAL S.A. (FR) | 2000-10-24 | — | — | US | disclosed |
| EP-1015643-A2 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | Hewlett-Packard Company (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6031086-A | HAVING DIMINISHED CHARGE BUT UNDIMINISHED ABILITY TO COMPLEX WITH NATURAL DNA AT LOW IONIC STRENGTHS; PREPARED BY REPLACING NATURAL NUCLEOTIDES WITH UNNATURAL ZWITTERIONIC NUCLEOTIDES; MEMBRANE PERMEABLE AND NUCLEASE RESISTANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0974672-A1 | Improved primers for AFLP amplification | KEYGENE N.V. (NL) | 2000-01-26 | — | — | EP | disclosed |
| WO-2000003038-A2 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | HEWLETT-PACKARD COMPANY (US) | 2000-01-20 | — | — | WO | disclosed |
| US-6005096-A | FOR OLIGONUCLEOTIDES THAT ARE MODIFIED TO ENHANCE THE BINDING AFFINITY AND TO BEAR DETECTABLE LABELS; FOR DIAGNOSTIC USE | GILEAD SCIENCES, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5985266-A | SENSITIZE TUMORS, RETROVIRUS COMPRISES OPERATIVELY LINKED TO A PROMOTER A GENE ENCODING A VIRAL THYMIDINE KINASE; SUCH THAT SAID TUMOR CELLS BECOME TRANSDUCED BY SAID RETROVIRUS AND EXPRESS SAID VIRAL THYMIDINE KINASE GENE; | HUMAN GENE THERAPY RESEARCH INSTITUTE (US) | 1999-11-16 | — | — | US | disclosed |
| US-5965364-A | Method for selecting functional deoxyribonucleotide derivatives | BENNER, STEVEN | 1999-10-12 | — | — | US | disclosed |
| EP-0923591-A1 | NOVEL BORONIC ACID-CONTAINING NUCLEIC ACIDS AND THEIR USE AS DIAGNOSTIC AGENTS | PROLINX, INC. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5876938-A | Use of boron-containing polynucleotides as diagnostic agents | PROLINX, INCORPORATED (US) | 1999-03-02 | — | — | US | disclosed |
| US-5831045-A | Boronic acid-containing polynucleotides | PORLINX, INCORPORATED (US) | 1998-11-03 | — | — | US | disclosed |
| US-5830653-A | ABILITY TO INHIBIT GENE EXPRESSION | GILEAD SCIENCES, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5831046-A | Boronic acid-contaning nucleic acid monomers | PROLINX, INCORPORATED (US) | 1998-11-03 | — | — | US | disclosed |
| US-5763588-A | Pyrimidine derivatives for labeled binding partners | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1998005672-A1 | NOVEL BORONIC ACID-CONTAINING NUCLEIC ACIDS AND THEIR USE AS DIAGNOSTIC AGENTS | PROLINX INCORPORATED (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0806956-A1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT AND MEDICAMENTS CONTAINING SAID NUCLEOSIDES | FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 1997-11-19 | — | — | EP | disclosed |
| EP-0755675-B1 | Dermatological and/or pharmaceutical composition, process of preparation and utilization | OREAL (FR) | 1997-09-17 | — | — | EP | disclosed |
| US-5645985-A | USED FOR DIAGNOSIS TO DETECT VIRUSES OR DISEASED CONDITIONS | GILEAD SCIENCES, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0755675-A1 | Dermatological and/or pharmaceutical composition, process of preparation and utilization | L'OREAL (FR) | 1997-01-29 | — | — | EP | disclosed |
| US-5596091-A | DNA AND RNA FOR GENE EXPRESSION FOR DIAGNOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996026743-A1 | RADIATION ENHANCED GENE THERAPY FOR TREATMENT OF TUMORS | HUMAN GENE THERAPY RESEARCH INSTITUTE (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1996023506-A1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT AND MEDICAMENTS CONTAINING SAID NUCLEOSIDES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 1996-08-08 | — | — | WO | disclosed |
| EP-0719272-A1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5502177-A | POLYCYCLIC STRUCTURE BOUND TO OLIGONUCLEOTIDE, FLUORESCENT LABEL, IMMUNOASSAY | GILEAD SCIENCES, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5434257-A | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages | GILEAD SCIENCES, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995011911-A1 | BINDING COMPETENT OLIGOMERS CONTAINING UNSATURATED 3',5' AND 2',5' LINKAGES | GLAXO WELLCOME INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| WO-1995007918-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993018776-A1 | COMBINATIONS OF COMPOUNDS HAVING ANTIVIRAL ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 1993-09-30 | — | — | WO | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| US-5151507-A | Alkynylamino-nucleotides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-29 | — | — | US | disclosed |
| US-4975433-A | DRUG DELIVERY FOR TREATING SKIN DISORDERS | UNIVERSITY OF FLORIDA (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0160079-B1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER, Sheldon B. (US) | 1990-01-31 | — | — | EP | disclosed |
| US-4894364-A | ANTITUMOR AGENTS | HALOGENETICS, INC. | 1990-01-16 | — | — | US | disclosed |
| EP-0339161-A1 | Novel fluorophosphonate nucleotide derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| EP-0335770-A2 | Novel fluorophosphonate nucleotide derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1989-10-04 | — | — | EP | disclosed |
| US-4845081-A | PRODRUGS, URACILS | UNIVERSITY OF FLORIDA (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0258412-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER, Sheldon B. (US) | 1988-03-09 | — | — | EP | disclosed |
| WO-1987004929-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER SHELDON B | 1987-08-27 | — | — | WO | disclosed |
| US-4594339-A | Veterinary medicine | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0160079-A4 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1986-05-14 | — | — | EP | disclosed |
| EP-0160079-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1985-11-06 | — | — | EP | disclosed |
| WO-1985001871-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER SHELDON B | 1985-05-09 | — | — | WO | disclosed |
| EP-0010205-B1 | 5-SUBSTITUTED 1-(2'-DEOXY-2'-SUBSTITUTED-BETA-D-ARABINOFURANOSYL) PYRIMIDINE NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sloan-Kettering Institute For Cancer Research (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | disclosed |
| US-4210638-A | 5-TRIFLUOROMETHYL-2'-DEOXYCYCTIDINE AND TETRAHYDROURIDINE OR 2'-DEOXYTETRAHYDROURIDINE | PCR, INC. (US) | 1980-07-01 | — | — | US | disclosed |
| EP-0010205-A1 | 5-Substituted 1-(2'-deoxy-2'-substituted-beta-D-arabinofuranosyl) pyrimidine nucleosides and pharmaceutical compositions containing them | Sloan-Kettering Institute For Cancer Research (US) | 1980-04-30 | — | — | EP | disclosed |
| US-4093715-A | 5-Iodo-5'-amino-2',5'-dideoxycytidine and the pharmaceutically acceptable salts thereof | RESEARCH CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4093715-A | 5-Iodo-5'-amino-2',5'-dideoxycytidine and the pharmaceutically acceptable salts thereof | RESEARCH CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11959137-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | DNMT1 86/4885ADRB1 4821/4885TK1 78/4885 |
| US-12606863-B2 | Bioluminescent detection of DNA synthesis | PCNA, MKI67, POLL | DNMT1 54/4885ADRB1 1776/4885TK1 6/4885 |
| US-20100292452-A1 | Modified nucleotides | ADAR, NT5C2, NSUN2 | DNMT1 241/4885ADRB1 2083/4885TK1 142/4885 |
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | DNMT1 274/4885ADRB1 4500/4885TK1 472/4885 |
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | DDX21, MBNL1, MECP2 | DNMT1 199/4885ADRB1 4348/4885TK1 2815/4885 |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | DNMT1 570/4885ADRB1 3876/4885TK1 62/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | DNMT1 570/4885ADRB1 3876/4885TK1 62/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | DNMT1 402/4885ADRB1 4637/4885TK1 22/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | DNMT1 402/4885ADRB1 4637/4885TK1 22/4885 |
| US-20250236911-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | DNMT1 146/4885ADRB1 4776/4885TK1 112/4885 |
| US-20090259030-A1 | STABILIZED NUCLEIC ACID DARK QUENCHER-FLUOROPHORE PROBES | DDX1, DDX18, DDX3X | DNMT1 177/4885ADRB1 4378/4885TK1 344/4885 |
| US-20220117992-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | UMPS, UPP1, TYMP | DNMT1 697/4885ADRB1 1973/4885TK1 19/4885 |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | DNMT1 252/4885ADRB1 2139/4885TK1 54/4885 |
| US-11920136-B2 | Transglutaminase-mediated conjugation | TGM2, TGM3, TGM1 | DNMT1 277/4885ADRB1 4834/4885TK1 310/4885 |
| US-20160326576-A1 | DUAL QUENCHER PROBES | DNA2, WRN, DDX42 | DNMT1 281/4885ADRB1 4693/4885TK1 1366/4885 |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | DNMT1 197/4885ADRB1 4437/4885TK1 107/4885 |
| US-20090069546-A1 | PYRAZOLE-BASED CYANINE DYE | CBR3, CYB5R3, TST | DNMT1 3683/4885ADRB1 1209/4885TK1 3542/4885 |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | DNMT1 146/4885ADRB1 4794/4885TK1 107/4885 |
| US-20180274024-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | DNMT1 146/4885ADRB1 4794/4885TK1 107/4885 |
| US-20100112711-A1 | METHOD OF DETECTING AMPLIFICATION OR DELETION IN GENOMIC DNA FRAGMENT | GLB1, GDA, DNTT | DNMT1 199/4885ADRB1 4446/4885TK1 7/4885 |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | DNMT1 336/4885ADRB1 3612/4885TK1 43/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | DNMT1 384/4885ADRB1 4067/4885TK1 156/4885 |
| US-10933068-B2 | Modulators of DUX4 for regulation of muscle function | DDX21, MBNL1, MECP2 | DNMT1 200/4885ADRB1 4347/4885TK1 2927/4885 |
| US-20200172896-A1 | EVOLUTION OF BIOACTIVE SEQUENCE-DEFINED SYNTHETIC POLYMERS USING DNA-TEMPLATED POLYMERIZATION | PCSK9, IL6, PCSK6 | DNMT1 473/4885ADRB1 4715/4885TK1 1078/4885 |
| US-20220257629-A1 | COMPOSITIONS AND METHODS FOR UPREGULATION OF HUMAN FETAL HEMOGLOBIN | HBB, HBG1, HBG2 | DNMT1 647/4885ADRB1 4766/4885TK1 1094/4885 |
| US-11180523-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | DNMT1 119/4885ADRB1 4810/4885TK1 10/4885 |
| US-20240376536-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | DNMT1 146/4885ADRB1 4776/4885TK1 112/4885 |
| US-20040049008-A1 | Templated molecules and methods for using such molecules | INTS6, ABL1, INMT | DNMT1 319/4885ADRB1 4209/4885TK1 772/4885 |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TPMT, KRAS, ACE | DNMT1 1643/4885ADRB1 335/4885TK1 2512/4885 |
| US-20120178919-A1 | RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF | TYMP, TK1, NUDT1 | DNMT1 950/4885ADRB1 1825/4885TK1 2/4885 |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | NUDT1, DHX15, DDX5 | DNMT1 336/4885ADRB1 3612/4885TK1 43/4885 |
| US-20220396830-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | RNGTT, NUDT1, DNTT | DNMT1 74/4885ADRB1 3842/4885TK1 44/4885 |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | DNMT1 127/4885ADRB1 4037/4885TK1 80/4885 |
| US-20190004055-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | POLM, RNGTT, TYMP | DNMT1 119/4885ADRB1 4810/4885TK1 10/4885 |
| US-20100016177-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | INTS6, ABL1, INMT | DNMT1 319/4885ADRB1 4209/4885TK1 772/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | DNMT1 1090/4885ADRB1 2217/4885TK1 1713/4885 |
| US-20220380768-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM1 | DNMT1 277/4885ADRB1 4834/4885TK1 310/4885 |
| US-20030143561-A1 | Nucleoside derivatives for library preparation | PNP, SAMHD1, DCTD | DNMT1 340/4885ADRB1 3875/4885TK1 70/4885 |
| US-20240343753-A1 | THERAPEUTIC COMPOUNDS | TET1, TET2, TET3 | DNMT1 20/4885ADRB1 3545/4885TK1 4778/4885 |
| US-20110118438-A1 | CYANINE-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM | ACR, RNGTT, NCL | DNMT1 716/4885ADRB1 1984/4885TK1 126/4885 |
| US-20170114058-A1 | COSMIC QUENCHERS | APEX1, NQO2, SQOR | DNMT1 61/4885ADRB1 4748/4885TK1 1431/4885 |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | DNMT1 235/4885ADRB1 2081/4885TK1 143/4885 |
| US-20210047646-A1 | Compositions Comprising Immune System Activators and Method of Using Same | RNASEL, RNASE1, RNASEH1 | DNMT1 306/4885ADRB1 4644/4885TK1 347/4885 |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | DNMT1 241/4885ADRB1 2083/4885TK1 142/4885 |
| US-20100081137-A1 | Click Chemistry for the Production of Reporter Molecules | DNTT, RNGTT, NSUN3 | DNMT1 552/4885ADRB1 4572/4885TK1 313/4885 |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | DNMT1 200/4885ADRB1 4880/4885TK1 92/4885 |
| US-20240382610-A1 | NECTIN-4 ANTIBODIES AND CONJUGATES | NECTIN4, FUT4, VCAM1 | DNMT1 1146/4885ADRB1 4494/4885TK1 3241/4885 |
| US-20140221639-A1 | RADIOLABELED NUCLEOSIDE ANALOGUE, AND PREPARATION METHOD AND USE THEREOF | TYMP, TK1, NUDT1 | DNMT1 950/4885ADRB1 1825/4885TK1 2/4885 |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | NT5C3B, CDA, RNGTT | DNMT1 127/4885ADRB1 4037/4885TK1 80/4885 |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | UMPS, UPP1, TYMP | DNMT1 697/4885ADRB1 1973/4885TK1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.